Amgen AMGN

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. BRIEF-UCB and Amgen announce results from several exploratory analyses of Phase 2 study of romosozumab

      Headlines

      Tue, 16 Sep 2014

      * UCB and Amgen announce results from several exploratory analyses of Phase 2 study of romosozumab

    2. From Barron’s, September 15, 2014 (Part 2)

      Commentary

      Sat, 13 Sep 2014

      http://online.barrons.com/public/page/9_0210-investorsentimentreadings.html Bullish stories: Amgen [ AMGN ; pg 18]; Allstate [ ALL ; pg 18]; Alibaba [ BABA ; pg 20]; Yahoo [ YHOO ; large stakes in BABA and Yahoo! Japan

    3. Biosimilars on the horizon in the U.S.

      Headlines

      Fri, 12 Sep 2014

      sell cheaper versions. Novartis ( NVS -0.7% ) submitted the first filing with the FDA in July for its version of Amgen 's ( AMGN -0.9% ) Neupogen (filgrastim). Regulatory clearance could happen as early as March 2015. Drug companies have

    4. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Thu, 11 Sep 2014

      pathway is finalized.The payoff from Amgen 's $10 billion acquisition of Onyx is ..... data won't be available until 2016. Amgen lacks the focus of some of its biotech ..... markets like immunology and oncology. Amgen has several drugs with annual sales surpassing

    5. There Is Further Upside Potential In Regeneron Pharmaceuticals

      Headlines

      Mon, 8 Sep 2014

      review voucher for alirocumab U.S. FDA submission, which has given them a chance to hit the market before Amgen Inc.'s (NASDAQ: AMGN ) evolocumab. Based on just these factors, I think there is further upside in Regeneron even as the stock

    6. Challenging Consensus On PCSK9 Inhibitors: Focus On Regeneron And Amgen

      Headlines

      Mon, 8 Sep 2014

      inhibitors, to the biotech companies Amgen (NASDAQ: AMGN ) and Regeneron (NASDAQ: REGN ..... companies supporting this site include AMGN and REGN, REGN's joint venture ..... and Eli Lilly (NYSE: LLY ). AMGN filed for FDA and European marketing

    7. Amgen Is A Great Biotech Stock With A Dividend Kicker

      Headlines

      Mon, 8 Sep 2014

      By Abba's Aces : The last time I analyzed Amgen Inc. (NASDAQ: AMGN ) on July 22, 2014, I stated, "I anticipate the ..... after earnings to realize some of the appreciation. Amgen is a global biotech company (the first of its kind

    8. Determining Celgene's Fair Value

      Headlines

      Wed, 3 Sep 2014

      By Jonathan Weber : Overview With a market capitalization of $76 billion, Celgene Corporation (NASDAQ: CELG ) is one of the biggest biotech companies in the world, although it reports sales of only $7 billion and earnings of $1.4 billion in the last twelve months. The company is headquartered in ...

    9. Amgen - Quickly Generating Growth

      Headlines

      Tue, 2 Sep 2014

      By Balanced Investing : Biotech giant Amgen Inc. (NASDAQ: AMGN ), who bills itself as the one of the first biotechnology firms, hit a 52-week high share price of $137.99 on Wednesday

    10. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      holding the largest biotechs (think Amgen , Gilead, Celgene, and Biogen ..... shoulder with established players like Amgen and Celgene. Thus, XBI's average ..... Celgene CELG, Gilead GILD, and Amgen AMGN , have led the rally, benefiting

    « Prev12345Next »
    Content Partners